Intuvie Holdings LLC
Letter data
- Company
- Intuvie Holdings LLC
- Recipient
- Frederick Lee | Chief Executive Officer | Intuvie Holdings LLC | Zyno Medical LLC | 177 Pine St | Natick | , | MA | 01760 | United States | Fred.Lee@intuvie.com
- Issue date
- 2026-07-16
- Posted date
- Not available
- FDA office
- Office of Medical Devices and Radiological Health Operations Div. 1 East
- Subject
- Not available
- Product
- Medical Devices
- CMS ID
- 629844
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Intuvie Holdings LLC
MARCS-CMS 629844 —
July 16, 2026
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Frederick Lee
Recipient Title
Chief Executive Officer
Intuvie Holdings LLC
Zyno Medical LLC
177 Pine St
Natick
,
MA
01760
United States
Fred.Lee@intuvie.com
Issuing Office:
Office of Medical Devices and Radiological Health Operations Div. 1 East
United States
Secondary Issuing Offices
United States
Dear Mr. Lee:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 629844, dated July 12, 2022). Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CAPT Cesar A. Perez, PhD, USPHS
Acting Deputy Director
Office of Regulatory Programs
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Content current as of:
07/21/2026
Regulated Product(s)
Medical Devices